Atrium Therapeutics, Inc. (RNA)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 2093101 · fiscal year ends in Dec
Closing price $8.31 on 30 Oct 2026; 52-week range $7.59 to $16.54.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Market value
- $142.2M
- Cash
- $72.3M
- Shares outstanding
- 17.1M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $3.0M | -$20.2M | -$1.18 |
| Q1 FY2026 | 31 Mar 2026 | $19.6M | -$16.6M | -$0.97 |
| Q2 FY2025 | 30 Jun 2025 | $3.8M | -$12.9M | -$0.75 |
| Q1 FY2025 | 31 Mar 2025 | $1.6M | -$7.4M | -$0.44 |
Company events
The newest 8-K filings of 8 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 27 Oct 2026 | 8-K | Other events | 8.01, 9.01 |
| 9 Oct 2026 | 8-K/A | Other events | 8.01 |
| 8 Oct 2026 | 8-K | Material agreement, Share sale, Other events | 1.01, 3.02, 8.01, 9.01 |
| 13 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 14 Jul 2026 | 8-K | Other events | 8.01, 9.01 |
| 14 May 2026 | 8-K | Results | 2.02, 9.01 |
| 27 Feb 2026 | 8-K | Change in control, Leadership change, Material agreement | 1.01, 5.01, 5.02, 9.01 |
| 26 Feb 2026 | 8-K | Investor update | 7.01, 9.01 |
Every filing
The newest filings with the SEC of 17 held.
| Filed | Form | Period |
|---|---|---|
| 27 Oct 2026 | 8-K | 27 Oct 2026 |
| 9 Oct 2026 | 8-K/A | 7 Oct 2026 |
| 8 Oct 2026 | 8-K | 7 Oct 2026 |
| 13 Aug 2026 | 10-Q | 30 Jun 2026 |
| 13 Aug 2026 | 8-K | 13 Aug 2026 |
| 14 Jul 2026 | 8-K | 14 Jul 2026 |
| 14 May 2026 | 10-Q | 31 Mar 2026 |
| 14 May 2026 | 8-K | 14 May 2026 |
| 17 Apr 2026 | S-8 | – |
| 27 Feb 2026 | 8-K | 26 Feb 2026 |
| 26 Feb 2026 | 8-K | 26 Feb 2026 |
| 26 Feb 2026 | S-8 | – |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | RA Capital Management, L.P. | 13G amended | 0% | 0 |
| 14 Aug 2026 | Sessa Capital IM, L.P. | 13G | 8.8% | 1.5M |
| 14 Aug 2026 | T. Rowe Price Associates, Inc. | 13G amended | 8.6% | 1.5M |
| 27 Jul 2026 | BlackRock, Inc. | 13G amended | 6.6% | 1.1M |
| 15 May 2026 | RA Capital Management, L.P. | 13G | 5.6% | 864.1K |
| 27 Apr 2026 | BlackRock, Inc. | 13G | 5.2% | 892.4K |
| 8 Apr 2026 | T. Rowe Price Associates, Inc. | 13G | 10% | 1.6M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 3.7M | +9.73% | 12.94 |
| 30 Sep 2026 | 3.4M | -0.06% | 8.27 |
| 15 Sep 2026 | 3.4M | +1.38% | 8.15 |
| 31 Aug 2026 | 3.4M | -3.72% | 19.79 |
| 14 Aug 2026 | 3.5M | -0.95% | 27.46 |
| 31 Jul 2026 | 3.5M | -2.15% | 28.39 |
| 15 Jul 2026 | 3.6M | -1.79% | 17.71 |
| 30 Jun 2026 | 3.7M | +1.29% | 12.52 |
Funds that hold it
From each fund's latest Form 13F.
199 funds held it at 30 Jun 2026: 79 added and 35 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Sessa Capital IM, L.P. | 1,500,000 | $20.2M | +948,609 |
| Price T Rowe Associates Inc. | 1,472,984 | $19.8M | -80,226 |
| BlackRock, Inc. | 1,447,476 | $19.5M | +242,185 |
| Crcm LP | 1,283,078 | $17.3M | +1,283,078 |
| Arbiter Partners Capital Management LLC | 783,864 | $10.5M | – |
| Vanguard Capital Management LLC | 730,831 | $9.8M | +103,962 |
| TIG Advisors, LLC | 561,533 | $7.6M | -46,019 |
| Cantor Fitzgerald, L. P. | 513,834 | $6.9M | – |
| Geode Capital Management, LLC | 386,929 | $5.2M | +67,098 |
| Two Sigma Investments, LP | 345,481 | $4.6M | +166,921 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.33T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $657.6B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $521.0B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $368.9B
- Novartis AG (NVS): revenue $54.5B, market value $306.8B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $289.5B
- Abbott Laboratories (ABT): revenue $46.6B, market value $183.8B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $178.6B
- Pfizer Inc. (PFE): revenue $63.7B, market value $173.8B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $141.6B